Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• drugs with low molecular weight, such as Doxil® (for delivery of doxorubicin) launched in 1995, DoceAqualip® (for delivery of docetaxel, devoid of polysorbate-80 and ethanol) launched in 2014, Onivyde® (for delivery of irinotecan) launched in 2015, and Vyxeos® (for synchronous delivery of cytarabine and

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

• Mamta Kumari,
• Amitabha Acharya and
• Praveen Thaggikuppe Krishnamurthy

Beilstein J. Nanotechnol. 2023, 14, 912–926, doi:10.3762/bjnano.14.75

• interaction between surface of the antibody and surface of the NP, which are oppositely charged [40]. This method is widely used for antibody conjugation because it is simple and less time-consuming. Recently, Choi et al. used an adsorption method to coat the surface of docetaxel nanocrystals (DTX-NCs) with

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• example of biomimetic NPs was described designed by Wang and co-workers. They used the natural tropism of mouse bone marrow mesenchymal cells (MSCs) for lung tumors for improved targeting of docetaxel (DTX) NPs (DTX-loaded polylactide-co-glycolide-b-poly(ethylene glycol); PLGA-b-PEG) loaded into the MSCs

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

• Sedat Ünal,
• Osman Doğan and
• Yeşim Aktaş

Beilstein J. Nanotechnol. 2022, 13, 1393–1407, doi:10.3762/bjnano.13.115

• drug delivery system loaded with docetaxel (DCX) as an anticancer drug, using poly(lactic-co-glycolic acid) (PLGA) as nanoparticle material, and modified with chitosan (CS) to gain mucoadhesive properties. In this context, an innovative nanoparticle formulation that can protect orally administered DCX

• : chitosan; docetaxel; intestinal tumors; oral drug delivery; PLGA; Introduction Cancer is one of the most common chronic diseases in the world, characterized by the uncontrolled proliferation and spread of cells [1]. To date, effective and safe treatment approaches for cancer treatment have not been fully

• colonic microflora. It has been reported that nanoparticles prepared with polymers such as chitosan, whose surface charge is positive, remain longer in the mucus due to electrostatic interaction with the negative charge of the aqueous mucin layer [15][29][30][31]. Docetaxel (DCX) is obtained semi

Alteration of nanomechanical properties of pancreatic cancer cells through anticancer drug treatment revealed by atomic force microscopy

• Xiaoteng Liang,
• Shuai Liu,
• Xiuchao Wang,
• Dan Xia and
• Qiang Li

Beilstein J. Nanotechnol. 2021, 12, 1372–1379, doi:10.3762/bjnano.12.101

• the physical properties of HeLa cells treated by docetaxel are different from that of untreated ones [9]. Therefore, the study of drug–cell interaction regarding cellular mechanics could be an effective way for drug evaluation. Important information, including drug efficacy and safety can be obtained

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• molecular targeting properties [40]. An LPHN was co-loaded with CUR and with docetaxel (82% and 90% average EE, respectively) and assayed in mice bearing PC3 (human prostate cancer) tumor xenografts [87]. The results showed higher cytotoxicity and a synergistic effect, which resulted in tumor growth

Comprehensive review on ultrasound-responsive theranostic nanomaterials: mechanisms, structures and medical applications

• Sepand Tehrani Fateh,
• Lida Moradi,
• Elmira Kohan,
• Michael R. Hamblin and
• Amin Shiralizadeh Dezfuli

Beilstein J. Nanotechnol. 2021, 12, 808–862, doi:10.3762/bjnano.12.64

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• . Also, in contrast to C225-NPs, free C225 antibody did not induce autophagy in cells [75]. Maya et al. reported the design and evaluation of EGFR-targeted cetuximab–chitosan cross-linked γ-poly(glutamic acid) nanoparticles loaded with docetaxel. The NPs were prepared by cross-linking the NH2 groups of

• pointed to increased apoptotic and necrotic cancer cell death after treatment with nanoscale carriers with specific EGFR targeting motifs, most probably due to improved uptake of docetaxel-loaded cross-linked nanoparticles and the EGFR receptor internalization [76]. There is a plethora of research

Targeting strategies for improving the efficacy of nanomedicine in oncology

• Gonzalo Villaverde and
• Alejandro Baeza

Beilstein J. Nanotechnol. 2019, 10, 168–181, doi:10.3762/bjnano.10.16

• constitutes a formidable barrier for tissue targeting not only in nanomedicine but also in common drug delivery [63]. In this case, liposomes were modified with Angiopep-2 and tLyP-1 homing and penetrating peptides for the simultaneous delivery of siRNA and (docetaxel) DTX. Angiopep-2 showed affinity to the

Enhanced antineoplastic/therapeutic efficacy using 5-fluorouracil-loaded calcium phosphate nanoparticles

• Shanid Mohiyuddin,
• Saba Naqvi and
• Gopinath Packirisamy

Beilstein J. Nanotechnol. 2018, 9, 2499–2515, doi:10.3762/bjnano.9.233

• for hepatoma targeted delivery of docetaxel with lactose as the targeting molecule [7]. Curcumin-loaded organically modified silica nanoparticles (ORMOSIL) were studied to check the potential anticancer property of ORMOSIL nanocarriers [8]. However, in some instances, after nanoparticle formation, the

Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment

• Cem Varan and
• Erem Bilensoy

Beilstein J. Nanotechnol. 2017, 8, 1446–1456, doi:10.3762/bjnano.8.144

• nanoparticles were in the range of 70–270 nm, depending on the preparation technique, polymer type and coating. Moreover, the chitosan coating significantly altered the surface charge of the nanoparticles to net positive values of +30 to +50 mV. The model drug docetaxel was successfully loaded into all

• particles, and the drug release rate from the nanoparticles was slowed down to 48 h by dispersing the nanoparticles in a hydroxypropyl cellulose film. Cell culture studies revealed that docetaxel-loaded nanoparticles cause higher cytotoxicity compared to the free docetaxel solution in DMSO. Conclusion

• : Docetaxel-loaded nanoparticles dispersed in a bioadhesive film were shown to be suitable for application of chemotherapeutics directly to the action site during surgical operation. The system was found to release chemotherapeutics for several days at the tumor site and neighboring tissue. This can be

Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation

• Kati Erdmann,
• Jessica Ringel,
• Silke Hampel,
• Manfred P. Wirth and
• Susanne Fuessel

Beilstein J. Nanotechnol. 2017, 8, 1307–1317, doi:10.3762/bjnano.8.132

• investigates the chemosensitizing potential of CNFs and CNTs to the conventional chemotherapeutics docetaxel (DTX) and mitomycin C (MMC), which have different molecular structures and mechanisms of action than platinum-based chemotherapeutics. DU-145 PCa cells were treated with DTX and MMC alone or in

• . Co-administration of chemotherapeutics with carbon nanomaterials could result in a reduction of the chemotherapeutic dosage and thus limit systemic side effects. Keywords: carbon nanomaterials; chemosensitization; docetaxel; mitomycin C; prostate cancer cells; Introduction According to the global

• neoadjuvant systemic chemotherapy with docetaxel (DTX) in combination with hormonal therapy prior to radical prostatectomy in patients with high-risk PCa [5][6][7]. The advantages of a neoadjuvant chemotherapy lie in the down-staging of the malignancy leading to better tumor resectability and improved overall